Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322673 · ClinicalTrials.gov registry record · Phase 2
Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by Symphony Evolution.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00322673 is a Phase 2 study that was terminated before completion, run by Symphony Evolution. The registered enrollment target is 14 participants.
The verdict
NCT00322673, a Phase 2 study, was terminated before completion, sponsored by Symphony Evolution.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML. XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC. c-Kit and FLT3 are receptors commonly expressed on AML blasts.
Interventions
- DRUG XL999
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00322673
The ClinicalTrials.gov registry entry for NCT00322673 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Symphony Evolution, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL999 is the first listed.
NCT00322673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00322673 about?
NCT00322673 is a clinical study titled "Study of XL999 in Patients With Acute Myeloid Leukemia (AML)". This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML. XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC. c...
What is the current status of trial NCT00322673?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2006-05. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00322673?
The interventions under investigation include: XL999 (DRUG).
Who is sponsoring clinical trial NCT00322673?
This trial is sponsored by Symphony Evolution, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.